Prevalence and characteristics of Escherichia coli sequence type 131 and its H30 and H30Rx subclones: A multicenter study from Korea

Diagnostic Microbiology and Infectious Disease

Volumn 84, Issue 2, 2016, Pages 97-101

  Kim, Soo Young ^a   Park, Yeon Joon ^a   Johnson, James R ^b   Yu, Jin Kyung ^a   Kim, Yong Kyun ^c   Kim, Yeong Sic ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Samkwang Medical Laboratories   (South Korea)

Author keywords

CTX M 15; Escherichia coli; Fluoroquinolone; H30; ST131; VagCD

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLONE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE MUTATION; GYRA GENE; KOREA; NONHUMAN; PARC GENE; PARE GENE; PRIORITY JOURNAL; REPLICON; ANALYSIS; CLASSIFICATION; CLINICAL TRIAL; ESCHERICHIA COLI INFECTIONS; GENETICS; GENOTYPE; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MISSENSE MUTATION; MOLECULAR EPIDEMIOLOGY; MULTICENTER STUDY; MULTILOCUS SEQUENCE TYPING; PLASMID; POLYMERASE CHAIN REACTION; PREVALENCE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; GENES, BACTERIAL; GENOTYPE; HOSPITALS; HUMANS; KOREA; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; MUTATION, MISSENSE; PLASMIDS; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 84954396970     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.10.016     Document Type: Article

References (31)

1. Banerjee R., Robicsek A., Kuskowski M.A., Porter S., Johnston B.D., Sokurenko E., et al. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010. Antimicrob Agents Chemother 2013, 57:6385-6388.
2. Carattoli A., Bertini A., Villa L., Falbo V., Hopkins K.L., Threlfall E.J. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 2005, 63:219-228.
3. Clermont O., Johnson J.R., Menard M., Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 2007, 57:129-136.
4. Clermont O., Lavollay M., Vimont S., Deschamps C., Forestier C., Branger C., et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008, 61:1024-1028.
5. Clermont O., Dhanji H., Upton M., Gibreel T., Fox A., Boyd D., et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009, 64:274-277.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement (M100-S22), 32(3) 2012, CLSI, Wayne, PA.
7. Colpan A., Johnston B., Porter S., Clabots C., Anway R., Thao L., et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013, 57:1256-1265.
8. Johnson J.R., Menard M., Johnston B., Kuskowski M.A., Nichol K., Zhanel G.G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009, 53:2733-2739.
9. Johnson J.R., Johnston B., Clabots C., Kuskowski M.A., Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010, 51:286-294.
10. Johnson J.R., Tchesnokova V., Johnston B., Clabots C., Roberts P.L., Billig M., et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013, 207:919-928.
11. Johnson J.R., Johnston B., Kuskowski M.A., Sokurenko E.V., Tchesnokova V. Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 compared with other fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother 2015, 59:4471-4480.
12. Komp Lindgren P., Karlsson A., Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003, 47:3222-3232.
13. Lafolie J., Nicolas-Chanoine M.H., Grenouillet F., Hocquet D., Bertrand X. Prevalence of Escherichia coli sequence type 131 and its H30 subclone among E. coli isolates in a French hospital. Int J Antimicrob Agents 2014, 44:466-468.
14. Lee M.Y., Choi H.J., Choi J.Y., Song M., Song Y., Kim S.W., et al. Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea. J Infect 2010, 60:146-153.
15. Matsumura Y., Yamamoto M., Nagao M., Ito Y., Takakura S., Ichiyama S., et al. Association of fluoroquinolone resistance, virulence genes, and IncF plasmids with extended-spectrum-β-lactamase-producing Escherichia coli sequence type 131 (ST131) and ST405 clonal groups. Antimicrob Agents Chemother 2013, 57:4736-4742.
16. Matsumura Y., Johnson J.R., Yamamoto M., Nagao M., Tanaka M., Takakura S., et al. CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. J Antimicrob Chemother 2015, 70:1639-1649.
17. Mnif B., Vimont S., Boyd A., Bourit E., Picard B., Branger C., et al. Molecular characterization of addiction systems of plasmids encoding extended-spectrum β-lactamases in Escherichia coli. J Antimicrob Chemother 2010, 65:1599-1603.
18. Mnif B., Harhour H., Jdidi J., Mahjoubi F., Genel N., Arlet G., et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli in Tunisia and characterization of their virulence factors and plasmid addiction systems. BMC Microbiol 2013, 25:147-155.
19. Nicolas-Chanoine M.H., Blanco J., Leflon-Guibout V., Demarty R., Alonso M.P., Caniça M.M., et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008, 61:273-281.
20. Nicolas-Chanoine M.H., Bertrand X., Madec J.Y. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014, 27:543-574.
21. Paltansing S., Kraakman M.E., Ras J.M., Wessels E., Bernards A.T. Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a Dutch teaching hospital reveals the presence of an Escherichia coli ST131 clone with a specific mutation in parE. J Antimicrob Chemother 2013, 68:40-45.
22. Park C.H., Robicsek A., Jacoby G.A., Sahm D., Hooper D.C. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006, 50:3953-3955.
23. Paul S., Linardopoulou E.V., Billig M., Tchesnokova V., Price L.B., Johnson J.R., et al. Role of homologous recombination in adaptive diversification of extraintestinal Escherichia coli. J Bacteriol 2013, 195:231-242.
24. Peirano G., van der Bij A.K., Freeman J.L., Poirel L., Nordmann P., Costello M., et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 2014, 58:3762-3767.
25. Price L.B., Johnson J.R., Aziz M., Clabots C., Johnston B., Tchesnokova V., et al. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 2013, 17:1-10.
26. Robicsek A., Strahilevitz J., Sahm D.F., Jacoby G.A., Hooper D.C. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006, 50:2872-2874.
27. Rogers B.A., Sidjabat H.E., Paterson D.L. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66:1-14.
28. Shin J., Kim D.H., Ko K.S. Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect 2011, 63:39-47.
29. Vimont S., Boyd A., Bleibtreu A., Bens M., Goujon J.M., Garry L., et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012, 7:e46547.
30. Woodford N., Fagan E.J., Ellington M.J. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β-lactamases. J Antimicrob Chemother 2006, 57:154-155.
31. Woodford N., Carattoli A., Karisik E., Underwood A., Ellington M.J., Livermore D.M. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob Agents Chemother 2009, 53:4472-4482.